Catalysts for $NVS

NOVARTIS AG earnings

NOVARTIS AG earnings

Novartis AG — zigakibart (Phase I/II Trial Completion)

NOVARTIS AG earnings

Novartis AG — asciminib hydrochloride (Phase II Trial Initiation)

COSENTYX (SECUKINUMAB) — FDA approval

COSENTYX (SECUKINUMAB) — FDA approval

COSENTYX (SECUKINUMAB) — FDA approval

COSENTYX (SECUKINUMAB) — FDA approval

ZOLEDRONIC ACID — FDA approval

PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN) — FDA approval

KESIMPTA (OFATUMUMAB) — FDA approval

TAFINLAR (DABRAFENIB MESYLATE) — FDA approval

MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approval

TAFINLAR (DABRAFENIB MESYLATE) — FDA approval

MEKINIST (TRAMETINIB) — FDA approval

COSENTYX (SECUKINUMAB) — FDA approval

COSENTYX (SECUKINUMAB) — FDA approval

SANDIMMUNE (CYCLOSPORINE) — FDA approval

SANDIMMUNE (CYCLOSPORINE) — FDA approval

SANDIMMUNE (CYCLOSPORINE) — FDA approval

LEQVIO (INCLISIRAN SODIUM) — FDA approval

LEQVIO (INCLISIRAN SODIUM) — FDA approval

GLEEVEC (IMATINIB MESYLATE) — FDA approval

SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval

VANRAFIA (ATRASENTAN HYDROCHLORIDE) — FDA approval

SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval

TEGRETOL (CARBAMAZEPINE) — FDA approval

RHAPSIDO (REMIBRUTINIB) — FDA approval

TEGRETOL (CARBAMAZEPINE) — FDA approval